How Pharmaceutical Tariffs Could Trigger Higher Drug Prices and Shortages

The specter of pharmaceutical tariffs looms over the U.S. healthcare landscape, threatening to disrupt the delicate balance of drug availability and affordability.

As tensions around global trade continue, potential tariffs on imported medications and ingredients could have far-reaching consequences for American patients and the healthcare system.

The complex web of pharmaceutical trade

The journey of a medication from production to pharmacy shelf involves multiple countries. Modern pharmaceuticals rely on intricate global supply chains where active ingredients, components, and finished products cross numerous borders before reaching patients.

This complexity makes the pharmaceutical industry particularly vulnerable to trade disruptions. The United States currently imports about $212 billion in drug products annually, with major suppliers including Ireland, Switzerland, Germany, Singapore, and India.

Timeline of pharmaceutical tariff concerns

The possibility of pharmaceutical tariffs has evolved rapidly in recent months. While medications were notably excluded from sweeping import duties announced in early April, subsequent statements have signaled a change in direction:

• April 8 brought an announcement about plans for a major pharmaceutical import tariff coming very shortly.
• By April 14, the White House launched an investigation into whether pharmaceutical imports pose a national security threat, often a precursor to implementing tariffs.

The potential price impact

If a 25% tariff were imposed on drug imports, prices could increase by nearly 13% and cost Americans approximately $51 billion annually. These increases would likely hit the generic drug market hardest, which comprises 90% of the U.S. drug supply.

Generic medications operate on a high-volume, low-margin business model. To maintain profitability while keeping prices low, these manufacturers depend on inexpensive imports of raw materials. When input costs rise due to tariffs, companies typically pass those increases on to consumers rather than operate at a loss.

With rising drug costs on the horizon, preventive care becomes even more important. Life Line Screening reveals hidden risks so you can act early. Book a screening today and have peace of mind.

Shortages: An existing problem that could worsen

Drug shortages already plague the U.S. healthcare system. As of early May, the FDA listed 89 medications in shortage, including treatments for cancer, tuberculosis, blood pressure issues, ADHD, pain, asthma, and anxiety.

Tariffs could exacerbate these shortages by disrupting established supply chains. When medications become scarce, prices typically rise—a pattern observed between 2016 and 2020 when drugs experiencing shortages saw price increases averaging 16.6%.

For patients, shortages mean more than just higher costs. Research shows they lead to increased medication errors, adverse events, and even higher mortality rates.

Global supply chain vulnerabilities

China plays a critical role in the global pharmaceutical supply chain, producing an estimated 20-40% of all active pharmaceutical ingredients (APIs) worldwide. U.S. medication imports from China doubled between 2020 and 2022, growing from 2.5% to 6% of total imports.

Tariffs could undermine these trade relationships, especially if other countries respond with retaliatory tariffs on American products, further complicating access to vital medications.

Get ahead and earn as much as possible on your emergency savings. For example, SoFi Checking pays a competitive APY on savings, plus a cash bonus for new members who set up direct deposit. (May change without notice.)

How the industry is responding

Major pharmaceutical companies have begun announcing significant investments in U.S. manufacturing, seemingly in response to tariff threats:

• Roche announced a $50 billion investment in U.S. manufacturing, research and development.
• Novartis committed $23 billion over five years to U.S. manufacturing.
• Johnson & Johnson pledged $55 billion over four years to expand U.S. production.
• Merck opened a $1 billion vaccine manufacturing facility as part of a larger investment.
• Eli Lilly unveiled plans for $27 billion to build four new U.S. manufacturing facilities.

Despite these moves, industry leaders remain concerned. Eli Lilly’s CEO has publicly stated that the tariffs could be difficult to recover from and suggested that companies may need to cut research and development budgets to absorb the added costs — a move that could hinder the development of new medications.

Who stands to lose the most?

While pharmaceutical companies work to navigate these challenges, patients, particularly those dependent on generic medications, may bear the heaviest burden. Generic drugs, which insurance companies typically cover more readily than brand-name alternatives, could see significant price increases.

For Americans already struggling with healthcare costs, tariff-induced price hikes could force difficult choices between medications and other necessities. Patients with chronic conditions requiring ongoing treatment would face sustained financial pressure.

The pharmaceutical tariff situation continues to evolve, but its potential to disrupt medication access and affordability remains a significant concern for healthcare providers, patients, and policymakers alike. As investments in domestic manufacturing ramp up, questions linger about whether these efforts can adequately replace established global supply chains without increasing costs for American consumers.

With health care costs on the rise and supply chains in flux, now is a good time to reevaluate your long-term financial plan. If you’ve got more than $100,000 in savings, get some advice from a pro. SmartAsset offers a free service that matches you to a vetted, fiduciary advisor in less than 5 minutes.